Plant Extract Composition for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes, particularly those involving metformin and other antidiabetic agents, come with significant contraindications and adverse effects, making it challenging to manage the condition effectively and safely, especially in patients with renal insufficiency, and often require multiple medications that can increase cardiovascular risk and mortality.
Innovation Solution
A composition comprising a mixture of extracts from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper (including piperine), which acts synergistically to improve carbohydrate and lipid metabolism, reducing blood sugar levels, improving insulin sensitivity, and addressing cardiovascular risk factors with fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin and other antidiabetic agents are used to treat type 2 diabetes, then blood sugar levels are reduced and insulin sensitivity is improved, but contraindications and adverse effects increase, especially in patients with renal insufficiency
Solution Approach 1:
The patent uses plant extracts (Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, and Piper) as natural, short-acting alternatives to long-term pharmaceutical interventions. These extracts provide therapeutic effects without the cumulative toxicity and renal accumulation issues associated with metformin, allowing patients to receive treatment even with compromised kidney function.
Solution Approach 2:
The plant extracts serve as intermediaries that bridge the gap between lifestyle modifications and strong pharmaceutical interventions. They provide a middle-ground therapeutic approach that is gentler than metformin but more effective than diet alone, reducing the need for aggressive pharmacological treatment and its associated side effects.
2Reliability
If multiple antidiabetic agents are combined to manage type 2 diabetes and cardiovascular risk factors, then metabolic control is improved, but the risk of serious side reactions and mortality increases
Solution Approach 1:
The patent combines multiple plant extracts with complementary mechanisms of action into a single formulation. This synergistic combination addresses multiple metabolic pathways (carbohydrate metabolism, lipid metabolism, insulin sensitivity) simultaneously, replacing the need for multiple separate pharmaceutical agents and their associated interaction risks.
Solution Approach 2:
The invention creates a composite therapeutic formulation integrating four different plant extracts, each contributing unique bioactive compounds. This composite approach provides multi-target therapy with a single product, reducing the complexity of polypharmacy and minimizing drug-drug interactions while maintaining comprehensive metabolic control.
3Productivity
If traditional antidiabetic treatments are initiated quickly to manage type 2 diabetes, then metabolic parameters are controlled, but the complexity of managing contraindications and adverse effects increases
Solution Approach 1:
The patent extracts the therapeutic benefits from complex pharmaceutical regimens and consolidates them into a single plant-based formulation. This extraction process removes the need to manage multiple separate medications, their contraindications, and their interactions, simplifying treatment while maintaining effectiveness.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The object of the invention is a composition comprising at least one mixture of molecules obtained from at least: - Chrysanthellum indicum, and - Cynara scolymus, and - Vaccinium myrtillus, said mixture of molecules also comprising piperine. This composition is particularly useful as a nutritional or health product for preventing and/or combating disorders of carbohydrate and/or lipid metabolism in humans or animals.